Drugs / anti-BCMA/GPRC5D bispecific CAR-T
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06793475 Background | Apr 2025 → Jun 2026 overdue | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-BCMA/GPRC5D bispecific CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06793475 ↗ |
| Modality | Cell therapy | “Autologous BCMA/GPRC5D bispecific CAR-T cells” NCT06793475 ↗ |
| Route | Intravenous | “infusion intravenously” NCT06793475 ↗ |
| Target | GPRC5D | “Autologous BCMA/GPRC5D bispecific CAR-T cells” NCT06793475 ↗ |